Stuart Arbuckle - Vertex Pharmaceuticals Chief Commercial Officer and Executive VP

VRTX -- USA Stock  

Earning Report: October 23, 2019  

  EVP
Mr. Stuart A. Arbuckle is Executive Vice President, Chief Commercial Officer of Vertex Pharmaceuticals Incorporated. Mr. Arbuckle is our Executive Vice President and Chief Commercial Officer, a position he has held since September 2012. Prior to joining us, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc., a 17, 000 person biotechnology company, from July 2004 through August 2012. Mr. Arbuckle has worked in the biopharmaceuticals industry since 1986, including more than 15 years at GlaxoSmithKline plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He served as a member of the Board of Directors of Cerulean Pharma, Inc. from June 2015 through July 2017 and has served as a member of the Board of Directors of ImmunoGen, Inc. since January 2018
Age: 52  EVP Since 2012      
617 341-6100  www.vrtx.com
Arbuckle holds a BSc in pharmacology and physiology from the University of Leeds.

Stuart Arbuckle Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 9.99 % which means that it generated profit of $9.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 56.25 % meaning that it created $56.25 on every $100 dollars invested by stockholders.
The company currently holds 656.95 M in liabilities with Debt to Equity (D/E) ratio of 12.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.67 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 3 records

EVP Since

Neil StahlRegeneron Pharmaceuticals
2014
Sharon KochanPerrigo Company Plc
2018
Todd KingmaPerrigo Company Plc
2006

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Current Sentiment - VRTX

Vertex Pharmaceuticals Investor Sentiment

Most of Macroaxis users are at this time bullish on Vertex Pharmaceuticals Incorpor. What is your outlook on investing in Vertex Pharmaceuticals Incorpor? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased over 100 shares of
2 hours ago
Traded for 24.76
Purchased over 200 shares of
2 hours ago
Traded for 53.38
Purchased over 60 shares of
2 hours ago
Traded for 78.1
Also please take a look at World Market Map. Please also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Search macroaxis.com